# The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

> **NCT02312206** · PHASE3 · TERMINATED · sponsor: **Prothena Biosciences Ltd.** · enrollment: 260 (actual)

## Conditions studied

- Primary Systemic (AL) Amyloidosis

## Interventions

- **DRUG:** NEOD001
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02312206
- **Lead sponsor:** Prothena Biosciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02
- **Primary completion:** 2018-05
- **Final completion:** 2018-05
- **Target enrollment:** 260 (ACTUAL)
- **Why stopped:** The VITAL study was terminated due to futility analysis
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02312206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02312206, "The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02312206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*